146 related articles for article (PubMed ID: 7691256)
1. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas.
Gerhartz HH; Engelhard M; Meusers P; Brittinger G; Wilmanns W; Schlimok G; Mueller P; Huhn D; Musch R; Siegert W
Blood; 1993 Oct; 82(8):2329-39. PubMed ID: 7691256
[TBL] [Abstract][Full Text] [Related]
2. Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF.
Engelhard M; Gerhartz H; Brittinger G; Engert A; Fuchs R; Geiseler B; Gerhartz D; Haunauske AR; Hartlapp HJ; Huhn D
Ann Oncol; 1994; 5 Suppl 2():123-5. PubMed ID: 7515644
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study.
Bergmann L; Karakas T; Knuth A; Lautenschläger G; Mitrou PS; Hoelzer D
Eur J Cancer; 1995 Dec; 31A(13-14):2164-8. PubMed ID: 8652236
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma; a placebo-controlled double blind phase III trial.
Kaku K; Takahashi M; Moriyama Y; Nakahata T; Masaoka T; Yoshida Y; Shibata A; Kaneko T; Miwa S
Leuk Lymphoma; 1993 Oct; 11(3-4):229-38. PubMed ID: 8260897
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to chemotherapy in aggressive non-Hodgkin's lymphomas.
Gerhartz HH; Engelhard M; Brittinger G; Schlimok G; Thiel E; Huber C; Emmerich B; Schadek C; Brandmaier R; Stern AC
Semin Oncol; 1994 Dec; 21(6 Suppl 16):25-8. PubMed ID: 7528447
[No Abstract] [Full Text] [Related]
6. COP-BLAM regimen combined with granulocyte colony-stimulating factor and high-grade non-Hodgkin's lymphoma.
Niitsu N; Umeda M
Eur J Haematol; 1995 Aug; 55(2):88-92. PubMed ID: 7543059
[TBL] [Abstract][Full Text] [Related]
7. A phase I/II study of dose and administration of non-glycosylated bacterially synthesized G-M CSF in chemotherapy-induced neutropenia in patients with non-Hodgkin's lymphomas.
Hovgaard D; Nissen NI
Leuk Lymphoma; 1992 Jun; 7(3):217-24. PubMed ID: 1477649
[TBL] [Abstract][Full Text] [Related]
8. Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma.
Niitsu N; Umeda M
Eur J Haematol; 1996 Mar; 56(3):163-7. PubMed ID: 8598236
[TBL] [Abstract][Full Text] [Related]
9. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
[TBL] [Abstract][Full Text] [Related]
10. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease.
Riccardi A; Gobbi P; Danova M; Giordano M; Pieresca C; Bertoloni D; Brugnatelli S; Ascari E
Haematologica; 1993; 78(1):44-8. PubMed ID: 7684012
[TBL] [Abstract][Full Text] [Related]
11. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: a phase I/II study.
Hovgaard DJ; Nissen NI
J Clin Oncol; 1992 Mar; 10(3):390-7. PubMed ID: 1740678
[TBL] [Abstract][Full Text] [Related]
12. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
Ho AD; Del Valle F; Haas R; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Thiel E; Andreesen R; Fiedler W
Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
[TBL] [Abstract][Full Text] [Related]
13. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial.
Kaplan LD; Kahn JO; Crowe S; Northfelt D; Neville P; Grossberg H; Abrams DI; Tracey J; Mills J; Volberding PA
J Clin Oncol; 1991 Jun; 9(6):929-40. PubMed ID: 2033429
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy with COP-BLAM III for intermediate and high-grade non-Hodgkin's lymphoma.
Niitsu N; Umeda M
Int J Hematol; 1994 Jul; 60(1):71-8. PubMed ID: 7522616
[TBL] [Abstract][Full Text] [Related]
15. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.
Zagonel V; Babare R; Merola MC; Talamini R; Lazzarini R; Tirelli U; Carbone A; Monfardini S
Ann Oncol; 1994; 5 Suppl 2():127-32. PubMed ID: 7515645
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen.
Sawada KI; Sato N; Kohno M; Hannda H; Yasukouchi T; Tanngo M; Hirayama A; Koike T
Leuk Lymphoma; 1995 Dec; 20(1-2):103-9. PubMed ID: 8750630
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission.
O'Day SJ; Rabinowe SN; Neuberg D; Freedman AS; Soiffer RJ; Spector NA; Robertson MJ; Anderson K; Whelan M; Pesek K
Blood; 1994 May; 83(9):2707-14. PubMed ID: 8167349
[TBL] [Abstract][Full Text] [Related]
18. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.
Gisselbrecht C; Haioun C; Lepage E; Bastion Y; Tilly H; Bosly A; Dupriez B; Marit G; Herbrecht R; Deconinck E; Marolleau JP; Yver A; Dabouz-Harrouche F; Coiffier B; Reyes F
Leuk Lymphoma; 1997 Apr; 25(3-4):289-300. PubMed ID: 9168439
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma.
Zinzani PL; Pavone E; Storti S; Moretti L; Fattori PP; Guardigni L; Falini B; Gobbi M; Gentilini P; Lauta VM; Bendandi M; Gherlinzoni F; Magagnoli M; Venturi S; Aitini E; Tabanelli M; Leone G; Liso V; Tura S
Blood; 1997 Jun; 89(11):3974-9. PubMed ID: 9166835
[TBL] [Abstract][Full Text] [Related]
20. THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for non-Hodgkin's lymphoma in elderly patients: a prospective study.
Niitsu N; Umeda M
Leukemia; 1997 Nov; 11(11):1817-20. PubMed ID: 9369412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
